CN115087672A - 抗人hvem(tnfrsf14)抗体及其用途 - Google Patents

抗人hvem(tnfrsf14)抗体及其用途 Download PDF

Info

Publication number
CN115087672A
CN115087672A CN202080096588.9A CN202080096588A CN115087672A CN 115087672 A CN115087672 A CN 115087672A CN 202080096588 A CN202080096588 A CN 202080096588A CN 115087672 A CN115087672 A CN 115087672A
Authority
CN
China
Prior art keywords
hvem
human
antibody
amino acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080096588.9A
Other languages
English (en)
Chinese (zh)
Inventor
路易·波恩
彼得勒斯·约翰内斯·西蒙斯
马赛尔·特奥多鲁斯·邓·哈托格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JJP Biologics Sp zoo
Original Assignee
JJP Biologics Sp zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JJP Biologics Sp zoo filed Critical JJP Biologics Sp zoo
Publication of CN115087672A publication Critical patent/CN115087672A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080096588.9A 2019-12-24 2020-12-24 抗人hvem(tnfrsf14)抗体及其用途 Pending CN115087672A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19219684 2019-12-24
EP19219684.8 2019-12-24
PCT/NL2020/050817 WO2021133170A1 (en) 2019-12-24 2020-12-24 Anti-human hvem (tnfrsf14) antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CN115087672A true CN115087672A (zh) 2022-09-20

Family

ID=69061152

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080096588.9A Pending CN115087672A (zh) 2019-12-24 2020-12-24 抗人hvem(tnfrsf14)抗体及其用途

Country Status (10)

Country Link
US (1) US12503516B2 (https=)
EP (1) EP4081541A1 (https=)
JP (1) JP7681025B2 (https=)
KR (1) KR20220128363A (https=)
CN (1) CN115087672A (https=)
AU (1) AU2020414265A1 (https=)
BR (1) BR112022012725A2 (https=)
CA (1) CA3162656A1 (https=)
MX (1) MX2022007855A (https=)
WO (1) WO2021133170A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4265639A2 (en) * 2020-12-15 2023-10-25 Medytox Inc. Anti-hvem antibody, and composition and method associated with same
US20240317871A1 (en) * 2020-12-30 2024-09-26 Immunomic Therapeutics, Inc. Anti-HVEM Antibodies
CN116715769B (zh) * 2022-05-26 2024-06-25 四川大学 抗hvem抗体、制备方法及其用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101896198A (zh) * 2007-06-01 2010-11-24 法国国家健康和医学研究院 治疗血液恶性肿瘤和自身免疫疾病的hvem配体
US20120064096A1 (en) * 2009-03-17 2012-03-15 Universite De La Mediterranee BTLA Antibodies and Uses Thereof
US20140220051A1 (en) * 2004-12-09 2014-08-07 La Jolla Institute For Allergy And Immunology Methods of modulating hvem, btla and cd160 cis complex response or signaling activity with soluble light polypeptide sequences
CN107922488A (zh) * 2015-04-02 2018-04-17 纪念斯隆-凯特琳癌症中心 Tnfrsf14/hvem蛋白及其使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US8188232B1 (en) * 2004-11-15 2012-05-29 Washington University In St. Louis Compositions and methods for modulating lymphocyte activity
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
WO2006090385A2 (en) * 2005-02-22 2006-08-31 Ramot At Tel-Aviv University Ltd. Protease inhibitors and method of screening thereof
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
TWI427085B (zh) * 2011-11-02 2014-02-21 國立成功大學 活化纖維蛋白溶酶原之抗體、其用途以及含有其之製劑
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
EP2985294A1 (en) * 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
US10562952B2 (en) * 2015-09-10 2020-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 chimeric antigen receptors
US10617720B2 (en) * 2016-10-20 2020-04-14 Miltenyi Biotech, GmbH Chimeric antigen receptor specific for tumor cells
US12036242B2 (en) * 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
WO2020095249A1 (en) * 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-liv1 immune cell cancer therapy
BR112021021645A2 (pt) * 2019-04-29 2021-12-21 4C Biomed Ltd Anticorpos anti-hvem e uso dos mesmos.
JP7716393B2 (ja) * 2019-10-04 2025-07-31 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗ｋｉｒ３ｄｌ３抗体およびそれらの使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140220051A1 (en) * 2004-12-09 2014-08-07 La Jolla Institute For Allergy And Immunology Methods of modulating hvem, btla and cd160 cis complex response or signaling activity with soluble light polypeptide sequences
CN101896198A (zh) * 2007-06-01 2010-11-24 法国国家健康和医学研究院 治疗血液恶性肿瘤和自身免疫疾病的hvem配体
US20120064096A1 (en) * 2009-03-17 2012-03-15 Universite De La Mediterranee BTLA Antibodies and Uses Thereof
CN107922488A (zh) * 2015-04-02 2018-04-17 纪念斯隆-凯特琳癌症中心 Tnfrsf14/hvem蛋白及其使用方法

Also Published As

Publication number Publication date
KR20220128363A (ko) 2022-09-20
US20230052646A1 (en) 2023-02-16
MX2022007855A (es) 2022-09-23
WO2021133170A1 (en) 2021-07-01
US12503516B2 (en) 2025-12-23
AU2020414265A1 (en) 2022-07-21
BR112022012725A2 (pt) 2022-11-16
JP2023522520A (ja) 2023-05-31
EP4081541A1 (en) 2022-11-02
JP7681025B2 (ja) 2025-05-21
CA3162656A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
JP7302990B2 (ja) ヒト及び非ヒトｃｄ３に結合可能なｃｄ３結合分子
US20240124583A1 (en) Proteins Comprising Kallikrein Related Paptidase 2 Antigen Binding Domains And Their Uses
DK2699590T3 (en) ENDOGLIN POLYPEPTIDES AND APPLICATIONS THEREOF
JP2022130393A (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
JP2019519223A (ja) 免疫調節タンパク質及び腫瘍抗原に結合する二重特異性結合タンパク質
TW202124415A (zh) 抗ｔｎｆｒ２抗體及使用方法
CN101668776A (zh) 拮抗剂ox40抗体及其在炎性和自身免疫疾病的治疗中的用途
RS57840B1 (sr) Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
CN115087672A (zh) 抗人hvem(tnfrsf14)抗体及其用途
US20250197491A1 (en) Compositions and methods for modulation of macrophage activity
JP2023522520A5 (https=)
RU2771964C2 (ru) Антитела против сигнал-регуляторного белка альфа и способы их применения
EA049801B1 (ru) Антитела против hvem человека (tnfrsf14) и их применение
AU2024322975A1 (en) Anti-ox40l antibody and use thereof
CN118139643A (zh) 与PD-L1、CD137和/或TGFβ的双特异性和三特异性结合蛋白及其用途
EA050351B1 (ru) Белки, содержащие антигенсвязывающие домены родственной калликреину пептидазы 2, и способы их применения
HK1190725A (en) Cd3-binding molecules capable of binding to human and non-human cd3
HK1190725B (en) Cd3-binding molecules capable of binding to human and non-human cd3

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination